Study: Less Is More For Testicular Cancer Chemo

Cutting the amount of chemotherapy in half reduced serious side effects that can have a lifelong impact on a patient's health, said the team of British researchers.
Source: WebMD Health - Category: Consumer Health News Source Type: news

Related Links:

Conclusion: Collated to the Comparison Group, the kidney function in TCSs became increasingly impaired during nearly three post-treatment decades, related to the treatment modality. Early detection and intervention of kidney dysfunction is important to reduce the risk of TCSs' long-term morbidity and mortality related to nephrotoxicity, such as cardio-vascular diseases. PMID: 32043400 [PubMed - as supplied by publisher]
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
Purpose of review Approximately 30% of clinical stage 1 (CS1) nonseminomatous germ cell tumours (NSGCT) and 15–20% of CS1 seminoma relapse without adjuvant treatment. Despite this, the 5-year survival for CS1 is 99%. The purpose of this review is to assess if active surveillance should be standard for all patients with CS1 testis cancer independent of risk factors. Recent findings Recent data from Princess Margaret Cancer Centre suggest a nonrisk-adapted surveillance approach avoids treatment in ∼70% of patients. Most relapse early at a median time of 7.4 months. The majority of relapses are confined to the ...
Source: Current Opinion in Urology - Category: Urology & Nephrology Tags: TESTICULAR CANCER: Edited by Axel Heidenreich and Siamak Daneshmand Source Type: research
Purpose of review Early-stage testicular cancers are highly curable. Following orchidectomy, management options for stage I disease include active surveillance, nerve-sparing retroperitoneal lymph node dissection (nsRPLND) and primary chemotherapy as recommended by the current guidelines. Primary RPLND has for decades played an integral part of treatment in patients with early-stage testicular germ cell tumors (TGCT), particularly in nonseminomatous germ cell tumors (NSGCT) with focus on reducing the long-term morbidity. We review the role of RPLND in stage I NSCGT as well as stage II A/B NSGCT and as seminoma. Recent f...
Source: Current Opinion in Urology - Category: Urology & Nephrology Tags: PENIS CANCER: Edited by Oscar R. Brouwer and Daher C. Chade Source Type: research
Purpose of review miRNAs 371 and 302/367 clusters are abundantly secreted in the blood of patients with active germ cell malignancy (aGCM), both seminoma and nonseminoma. The serum concentration of those micro-RNAs correlates with tumor burden and to the activity of specific treatments; therefore, representing attractive biomarkers for the diagnosis and follow-up of patients with germ cell tumors. This review summarizes the most relevant evidence supporting their clinical validity in germ cell tumors. Recent findings Several retrospective studies have reported high sensitivity and specificity of those micro-RNAs in id...
Source: Current Opinion in Urology - Category: Urology & Nephrology Tags: PENIS CANCER: Edited by Oscar R. Brouwer and Daher C. Chade Source Type: research
Up to 50% of men with poor prognosis, non-seminoma germ cell tumours (GCTs) die with standard BEP (bleomycin, etoposide and cisplatin) chemotherapy. An intensive regimen, CBOP/BEP (carboplatin, bleomycin, vincristine and cisplatin/BEP), met response targets in a randomised, phase II trial (74% complete response or partial response marker negative, 90% confidence interval (CI) 61% –85%).
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Original Research Source Type: research
Abstract INTRODUCTION: To determine the benefits of alvimopan and multimodal pain management strategies in men undergoing retroperitoneal lymph node dissection for testicular cancer. METHODS: A retrospective cohort study was completed in men undergoing retroperitoneal lymph node dissection from January 2017 to May 2018. Patients were placed into the 3-drug, 2-drug, and control cohorts as a result of a prospectively determined protocol during the study period. Men in the 3-drug group were managed using alvimopan 12 mg PO the morning of surgery then BID until bowel movement, gabapentin 300 mg daily, and acetami...
Source: Urologic Oncology - Category: Urology & Nephrology Authors: Tags: Urol Oncol Source Type: research
THURSDAY, Jan. 9, 2020 -- Treatment with half the typical amount of chemotherapy can still prevent the return of one type of testicular cancer, a new study suggests. Giving patients with the " non-seminoma " form of testicular tumor just one cycle of...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
A clinical trial showed that giving men with testicular cancer one cycle of chemotherapy was as effective at preventing cancer from coming back as the two cycles normally used, and carried fewer side effects.
Source: Health News - UPI.com - Category: Consumer Health News Source Type: news
A new study suggests that men could be spared some long-term toxic side effects without compromising the effectiveness of treatment by halving the amount of chemotherapy they receive after surgery.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Source Type: news
Doctors say the number of cycles of chemotherapy can be halved without increasing risk of a relapse.
Source: BBC News | Health | UK Edition - Category: Consumer Health News Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Health | Study | Testicular Cancer | UK Health